Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
A J
AJ
Krentz
C J
CJ
Bailey
A
A
Melander
D056486:Chemical and Drug Induced Liver Injury; D002839:Chromans / Q000009:adverse effects / Q000627:therapeutic use; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D007333:Insulin Resistance; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077288:Troglitazone; D000077205:Pioglitazone